Art Unit: 1617

Ŋ	229 (New).	The method of claim 156, further comprising co-administering an estrogen or an ACE inhibitor.
	230 (New).	The method of claim 167, further comprising co-administering an estrogen or an ACE inhibitor.
	231 (New).	The method of claim 181, further comprising co-administering an estrogen or an ACE inhibitor.
	232 (New).	The method of claim 187, further comprising co-administering an estrogen or an ACE inhibitor.
	233 (New).	The method of claim 192, further comprising co-administering an estrogen or an ACE inhibitor.
	234 (New).	The method of claim 193 further comprising co-administering an estrogen or an ACE inhibitor.
	235 (New).	A composition, comprising:  an HMG-CoA reductase inhibitor, and
		an agent selected from the group consisting of an estrogen and an ACE inhibitor.

## <u>REMARKS</u>

New claims 224-235 are added.

Please withdraw claim 235 from consideration (as it is drawn to non-elected subject matter).

Support for the foregoing additions can be found at least in pages 18, line 31 to page 19, line 28, of the specification as filed. No new matter has been added.

Applicants added claim 235 so that the claim's subject matter and scope are explicitly made of record; please withdraw claim 235 from consideration as it is drawn to non-elected subject matter. Applicants reserve the right to pursue non-elected and canceled matter in subsequent applications.

Respectfully Submitted,

Edward R. Gates, Reg. No.: 31,616

WOLF, GREENFIELD & SACKS, P.C.

600 Atlantic Avenue Boston, MA 02210-2211

Date: March 16, 2001

Attorney's Docket No.: R0547/7007

**XNDD**